Funding for this research was provided by:
Signe ja Ane Gyllenbergin Säätiö
Ida Montinin Säätiö
Academy of Finland (292605 and 287224)
Research grant from Incyte.
S.M. has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb (not related to this study).
Received: 27 July 2020
Revised: 30 September 2020
Accepted: 25 October 2020
First Online: 9 November 2020
Compliance with ethical standards
: This work was supported by Academy of Finland (grant no. 292605 and 287224), the Finnish Funding Agency for Innovation (Dnro 6113/31/2016), Finnish special governmental subsidy for health sciences, research and training, Signe and Ane Gyllenberg Foundation, Finnish Cultural Foundation, Ida Montin Foundation, Nordic Cancer Union, Helsinki Institute of Life Science, Cancer Foundation Finland, Relander Foundation, Incyte Nordic Hematology grant, and Finnish Cancer Institute. SM has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb (not related to this study). SAA and HH have received research funding from Incyte.